# WIA-BIO-009: Drug Discovery Specification v1.0

> **Standard ID:** WIA-BIO-009
> **Version:** 1.0.0
> **Published:** 2025-12-26
> **Status:** Active
> **Authors:** WIA Biotechnology Research Group

---

## Table of Contents

1. [Introduction](#1-introduction)
2. [Target Identification & Validation](#2-target-identification--validation)
3. [Hit Discovery & Screening](#3-hit-discovery--screening)
4. [Lead Optimization](#4-lead-optimization)
5. [ADMET Prediction](#5-admet-prediction)
6. [Preclinical Studies](#6-preclinical-studies)
7. [Clinical Trial Standards](#7-clinical-trial-standards)
8. [Regulatory Submission](#8-regulatory-submission)
9. [Implementation Guidelines](#9-implementation-guidelines)
10. [References](#10-references)

---

## 1. Introduction

### 1.1 Purpose

This specification defines a comprehensive, standardized framework for drug discovery and development, from initial target identification through regulatory approval.

### 1.2 Scope

The standard covers:
- Target identification and validation methods
- High-throughput screening protocols
- Medicinal chemistry optimization strategies
- Computational ADMET prediction
- Preclinical study requirements
- Clinical trial data standards
- Regulatory submission formats

### 1.3 Philosophy

**弘益人間 (Benefit All Humanity)** - This standard aims to accelerate drug discovery, reduce development costs, and ensure medicines reach patients faster while maintaining rigorous safety standards.

### 1.4 Terminology

- **Target**: Biological molecule (protein, RNA, DNA) involved in disease
- **Hit**: Compound showing desired activity in primary screen
- **Lead**: Optimized compound entering preclinical development
- **IC50**: Half maximal inhibitory concentration
- **ADMET**: Absorption, Distribution, Metabolism, Excretion, Toxicity
- **IND**: Investigational New Drug application
- **NDA**: New Drug Application

---

## 2. Target Identification & Validation

### 2.1 Target Selection Criteria

A valid drug target must satisfy:

```
Validation Score = (Disease Association × Druggability × Safety) / Complexity
```

Where:
- `Disease Association`: Genetic/biochemical evidence (0-1)
- `Druggability`: Chemical tractability score (0-1)
- `Safety`: Toxicity risk assessment (0-1)
- `Complexity`: Development difficulty factor (1-10)

**Minimum threshold**: Validation Score ≥ 0.5

### 2.2 Target Classes

| Class | Examples | Druggability | Success Rate |
|-------|----------|--------------|--------------|
| Enzymes | Kinases, Proteases | High (0.8-1.0) | 25% |
| GPCRs | Adrenergic, Dopamine | High (0.7-0.9) | 30% |
| Ion Channels | Nav, Cav, Kv | Medium (0.5-0.7) | 15% |
| Nuclear Receptors | ER, AR, GR | High (0.8-1.0) | 35% |
| Protein-Protein | PD-1/PD-L1 | Low (0.2-0.4) | 5% |

### 2.3 Validation Methods

#### 2.3.1 Genetic Validation
```
Phenotype Score = (KO Effect × Disease Relevance) / Off-Target Effects
```

Methods:
- CRISPR/Cas9 knockout
- RNAi knockdown
- Patient genetics (GWAS)
- Mendelian disease association

#### 2.3.2 Chemical Validation
```
Tool Compound Quality = Potency × Selectivity × Cell Permeability
```

Requirements:
- IC50 < 100 nM (potency)
- Selectivity > 100× over off-targets
- Cell permeability (Caco-2 > 50 nm/s)

### 2.4 Target Structure Determination

Preferred methods (in order):
1. **X-ray Crystallography**: Resolution < 2.5 Å
2. **Cryo-EM**: Resolution < 3.5 Å
3. **NMR**: For proteins < 30 kDa
4. **Homology Modeling**: If >50% sequence identity to known structure

---

## 3. Hit Discovery & Screening

### 3.1 Screening Strategies

#### 3.1.1 High-Throughput Screening (HTS)
```
Z-factor = 1 - (3 × (σp + σn)) / |μp - μn|
```

Where:
- `σp, σn` = Standard deviations of positive/negative controls
- `μp, μn` = Means of positive/negative controls
- **Acceptable**: Z-factor ≥ 0.5

#### 3.1.2 Fragment-Based Drug Discovery (FBDD)
```
Ligand Efficiency (LE) = -ΔG / (Heavy Atom Count)
```

Where:
- `ΔG = RT ln(Kd)` = Binding free energy
- **Good fragment**: LE > 0.3 kcal/mol/atom

#### 3.1.3 Virtual Screening
```
Docking Score = Evdw + Eelec + Edesolv + Econformational
```

Enrichment factor:
```
EF = (Hitsₛ / Nₛ) / (Hitsₜ / Nₜ)
```

Where:
- `Hitsₛ` = Hits in screened subset
- `Nₛ` = Size of screened subset
- **Good virtual screen**: EF > 10

### 3.2 Hit Criteria

A compound qualifies as a hit if:

1. **Activity**: IC50 < 10 μM
2. **Reproducibility**: CV < 20% (n=3 replicates)
3. **Dose-Response**: Hill slope 0.5-2.0
4. **Orthogonal Confirmation**: ≥2 independent assays
5. **Non-PAINS**: Not in Pan-Assay Interference Compounds list

### 3.3 Assay Development

#### 3.3.1 Biochemical Assays
```
Signal/Background = (Signalₘₐₓ - Signalₘᵢₙ) / Signalₘᵢₙ
```

**Minimum**: S/B ≥ 5

#### 3.3.2 Cell-Based Assays
```
Window Coefficient = |μₚ - μₙ| / (σₚ + σₙ)
```

**Minimum**: WC ≥ 3

### 3.4 Counter-Screening

All hits must be tested against:
- **Cytotoxicity**: MTT/CellTiter-Glo (CC50 > 50 μM)
- **Aggregation**: Dynamic light scattering
- **Redox Cycling**: DTT sensitivity test
- **Fluorescence Interference**: Quenching assay

---

## 4. Lead Optimization

### 4.1 Optimization Objectives

Multi-parameter optimization (MPO) score:
```
MPO = Σ(wᵢ × Tᵢ(pᵢ))
```

Where:
- `wᵢ` = Weight for parameter i
- `Tᵢ` = Transformation function (sigmoid)
- `pᵢ` = Parameter value

### 4.2 Potency Optimization

Target progression:
```
Hit (IC50 ~ 1-10 μM) → Lead (IC50 ~ 10-100 nM) → Clinical Candidate (IC50 < 10 nM)
```

Structure-Activity Relationship (SAR):
```
ΔpIC50 = log₁₀(IC50ᵣₑ𝒻) - log₁₀(IC50ₙₑw)
```

**Significant improvement**: ΔpIC50 ≥ 0.5 (3-fold increase)

### 4.3 Physicochemical Properties

#### 4.3.1 Lipinski's Rule of Five
For oral drugs:
- Molecular Weight ≤ 500 Da
- LogP ≤ 5
- H-bond Donors ≤ 5
- H-bond Acceptors ≤ 10

#### 4.3.2 Extended Lipinski
- Polar Surface Area (PSA): 40-140 Ų
- Rotatable Bonds: ≤ 10
- Aromatic Rings: ≤ 3
- Sp³ Carbon Fraction: > 0.25

### 4.4 Selectivity Optimization

```
Selectivity Index = IC50(off-target) / IC50(on-target)
```

**Minimum**: SI ≥ 100 for most similar off-target

### 4.5 Medicinal Chemistry Strategies

#### 4.5.1 Scaffold Hopping
Replace core while maintaining:
- Key interactions (H-bonds, π-stacking)
- 3D shape similarity (Tanimoto > 0.7)
- Lipophilicity (ΔLogP < 1)

#### 4.5.2 Bioisosteric Replacement
Common bioisosteres:
- COOH ↔ Tetrazole
- Benzene ↔ Pyridine
- CH₂ ↔ O, S, NH
- C=O ↔ C=S

#### 4.5.3 Conformational Restriction
```
ΔΔG(binding) = -RT ln(f)
```

Where `f` = fraction of bioactive conformer

---

## 5. ADMET Prediction

### 5.1 Absorption

#### 5.1.1 Solubility
```
LogS = -0.01 × (MW - 200) - LogP - 0.01 × TPSA
```

**Target**: LogS > -4 (>100 μM)

#### 5.1.2 Permeability
Caco-2 model:
```
Papp = (dQ/dt) × (1 / (A × C₀))
```

Where:
- `dQ/dt` = Transport rate
- `A` = Membrane area
- `C₀` = Initial concentration

**High permeability**: Papp > 100 nm/s

### 5.2 Distribution

#### 5.2.1 Volume of Distribution
```
Vd = (Dose × F) / AUC × ke
```

**Typical range**: 0.1-10 L/kg

#### 5.2.2 Plasma Protein Binding
```
fu = [Drug]ᵤₙᵦₒᵤₙ𝒹 / [Drug]ₜₒₜₐₗ
```

Where `fu` = fraction unbound

**Target**: 0.1 < fu < 0.5 (10-50% free)

### 5.3 Metabolism

#### 5.3.1 Metabolic Stability
```
CLint = (0.693 / t½) × (Vᵢₙcᵤᵦₐₜᵢₒₙ / mg protein)
```

**Good stability**: t½ > 60 min in liver microsomes

#### 5.3.2 CYP450 Interactions
Test against main isoforms:
- CYP3A4 (50% of drugs)
- CYP2D6 (25% of drugs)
- CYP2C9, 2C19, 1A2

**Acceptable**: IC50 > 10 μM for all CYPs

### 5.4 Excretion

#### 5.4.1 Clearance
```
CL = Dose × F / AUC
```

**Target**: CL < 20 mL/min/kg

#### 5.4.2 Half-Life
```
t½ = 0.693 × Vd / CL
```

**Optimal**: 4-12 hours for QD dosing

### 5.5 Toxicity

#### 5.5.1 hERG Inhibition
```
TdP Risk = (hERG IC50 / Cmax) < 30
```

**Safe**: hERG IC50 / Cmax > 30

#### 5.5.2 Genotoxicity
Required tests:
- Ames test (bacterial mutation)
- Micronucleus assay (chromosomal damage)
- Comet assay (DNA strand breaks)

**Pass**: All negative

#### 5.5.3 Hepatotoxicity
Markers:
- ALT/AST elevation (< 2× ULN)
- Bilirubin (< 1.5× ULN)
- Alkaline phosphatase (< 1.5× ULN)

---

## 6. Preclinical Studies

### 6.1 In Vitro Studies

#### 6.1.1 Target Engagement
Methods:
- Cellular thermal shift assay (CETSA)
- Drug affinity responsive target stability (DARTS)
- Kinetic analysis (kon, koff, Kd)

```
Kd = koff / kon
```

**Strong binder**: Kd < 10 nM

#### 6.1.2 Functional Assays
Measure:
- Signal transduction (Western blot)
- Gene expression (qPCR, RNA-seq)
- Phenotypic readout (cell proliferation, apoptosis)

### 6.2 In Vivo Pharmacokinetics

#### 6.2.1 PK Parameters
```
Bioavailability (F%) = (AUCpo × Doseiv) / (AUCiv × Dosepo) × 100
```

**Target**: F > 30% for oral drugs

#### 6.2.2 Species Selection
Standard species:
- Mouse (preliminary PK)
- Rat (toxicology, efficacy)
- Dog (non-rodent toxicology)
- Monkey (if needed for NHP data)

### 6.3 Efficacy Studies

#### 6.3.1 Disease Models
Requirements:
- Relevant biology (target expressed)
- Predictive validity (translates to humans)
- Reproducible (CV < 20%)

#### 6.3.2 Efficacy Metrics
```
% Tumor Growth Inhibition = (1 - ΔTreated / ΔControl) × 100
```

**Minimum**: TGI > 60% for oncology

### 6.4 Toxicology

#### 6.4.1 Acute Toxicity
```
LD50 = dose causing 50% lethality
```

**Acceptable**: LD50 > 500 mg/kg

#### 6.4.2 Repeat-Dose Toxicity
Durations:
- 14-day (dose-finding)
- 28-day (IND-enabling)
- 90-day (NDA-enabling)

**Safety margin**: NOAEL / Therapeutic Dose > 10

---

## 7. Clinical Trial Standards

### 7.1 Phase I (Safety & PK)

#### 7.1.1 Dose Escalation
Starting dose:
```
HED = (Animal NOAEL × (Wanimal / Whuman)^0.33) / Safety Factor
```

Where:
- HED = Human Equivalent Dose
- Safety Factor = 10

#### 7.1.2 Maximum Tolerated Dose
```
MTD = highest dose with DLT rate < 33%
```

DLT = Dose-Limiting Toxicity

### 7.2 Phase II (Efficacy)

#### 7.2.1 Sample Size
```
n = 2 × (Zα + Zβ)² × σ² / Δ²
```

Where:
- `Zα` = Significance level (1.96 for α=0.05)
- `Zβ` = Power (0.84 for 80% power)
- `σ` = Standard deviation
- `Δ` = Effect size

#### 7.2.2 Efficacy Endpoints
Primary:
- Objective response rate (ORR)
- Progression-free survival (PFS)
- Overall survival (OS)

Secondary:
- Quality of life (QoL)
- Biomarkers
- PK/PD relationship

### 7.3 Phase III (Confirmatory)

#### 7.3.1 Study Design
- Randomized, double-blind, placebo-controlled
- Multi-center (≥ 10 sites)
- Adequate power (≥ 90%)

#### 7.3.2 Statistical Analysis
```
Hazard Ratio = (Events in Treatment) / (Events in Control)
```

**Significant**: HR with 95% CI not crossing 1.0, p < 0.05

### 7.4 Phase IV (Post-Marketing)

Monitor for:
- Rare adverse events (< 1%)
- Long-term efficacy
- Drug-drug interactions
- Special populations

---

## 8. Regulatory Submission

### 8.1 IND Application

Required sections:
1. **Form FDA 1571**
2. **Investigator's Brochure**
3. **Protocol(s)**
4. **Chemistry, Manufacturing, Controls (CMC)**
5. **Pharmacology & Toxicology**
6. **Previous Human Experience**
7. **Additional Information**

### 8.2 NDA/BLA Structure

#### 8.2.1 Common Technical Document (CTD)
```
CTD Structure:
├── Module 1: Regional Administrative Information
├── Module 2: Common Technical Document Summaries
├── Module 3: Quality (CMC)
├── Module 4: Nonclinical Study Reports
└── Module 5: Clinical Study Reports
```

#### 8.2.2 Quality Requirements
- Drug substance: ≥ 98% purity
- Drug product: ≥ 95% assay (90-110% of label claim)
- Stability: ICH Q1A guidelines

### 8.3 Risk-Benefit Analysis

```
Therapeutic Index = TD50 / ED50
```

Where:
- `TD50` = Toxic dose (50%)
- `ED50` = Effective dose (50%)

**Acceptable**: TI > 3

### 8.4 Labeling Requirements

#### 8.4.1 Highlights
- Indications and usage
- Dosage and administration
- Contraindications
- Warnings and precautions

#### 8.4.2 Full Prescribing Information
- Clinical pharmacology
- Adverse reactions
- Drug interactions
- Use in specific populations

---

## 9. Implementation Guidelines

### 9.1 Required Components

Any WIA-BIO-009 compliant system must include:

1. **Compound Registry**: Unique IDs, structures, properties
2. **Assay Database**: Protocols, results, quality metrics
3. **ADMET Predictor**: Computational models
4. **Clinical Data Manager**: EDC system
5. **Regulatory Module**: Document generation

### 9.2 API Interface

#### 9.2.1 Screen Compounds
```typescript
interface ScreeningRequest {
  target: DrugTarget;
  compounds: Compound[];
  assayType: 'binding' | 'enzymatic' | 'cellular' | 'phenotypic';
  threshold: {
    ic50?: number;
    ec50?: number;
    ki?: number;
  };
}

interface ScreeningResult {
  hits: CompoundHit[];
  statistics: {
    totalCompounds: number;
    hitRate: number;
    zFactor: number;
  };
}
```

#### 9.2.2 Predict ADMET
```typescript
interface ADMETRequest {
  smiles: string;
  models: ('solubility' | 'permeability' | 'metabolism' | 'hERG' | 'cyp450')[];
}

interface ADMETProfile {
  absorption: {
    solubility: number;        // LogS
    permeability: number;      // Papp (nm/s)
    bioavailability: number;   // F%
  };
  distribution: {
    volumeOfDistribution: number;  // Vd (L/kg)
    plasmaProteinBinding: number;  // %
  };
  metabolism: {
    halfLife: number;              // t½ (h)
    clearance: number;             // CL (mL/min/kg)
    cyp450Inhibition: Record<string, number>;  // IC50 values
  };
  toxicity: {
    hERG_IC50: number;
    ames: 'positive' | 'negative' | 'inconclusive';
    hepatotoxicityRisk: 'low' | 'medium' | 'high';
  };
}
```

### 9.3 Data Formats

#### 9.3.1 Compound Structure
```json
{
  "id": "WIA-BIO-001",
  "name": "Aspirin",
  "smiles": "CC(=O)Oc1ccccc1C(=O)O",
  "inchi": "InChI=1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)",
  "molecularWeight": 180.16,
  "formula": "C9H8O4"
}
```

#### 9.3.2 Assay Data
```json
{
  "assayId": "EGFR-Kinase-001",
  "compoundId": "WIA-BIO-001",
  "targetName": "EGFR",
  "assayType": "enzymatic",
  "ic50": 1.2e-6,
  "ic50_unit": "M",
  "hillSlope": 1.1,
  "r_squared": 0.98,
  "replicates": 3,
  "cv_percent": 8.5,
  "date": "2025-12-26"
}
```

### 9.4 Error Handling

Standard error codes:

| Code | Meaning | Action |
|------|---------|--------|
| B001 | Invalid SMILES | Correct structure |
| B002 | Target not found | Check target database |
| B003 | Assay quality low | Repeat experiment |
| B004 | ADMET prediction failed | Use experimental data |
| B005 | Toxicity alert | Halt development |
| B006 | Regulatory non-compliance | Update documentation |

---

## 10. References

### 10.1 Scientific Literature

1. Lipinski, C.A., et al. (1997). "Experimental and computational approaches to estimate solubility and permeability"
2. Hopkins, A.L., Groom, C.R. (2002). "The druggable genome"
3. Zhang, M.Q., Wilkinson, B. (2007). "Drug discovery beyond the 'rule-of-five'"
4. Waring, M.J., et al. (2015). "An analysis of the attrition of drug candidates"
5. Morgan, P., et al. (2018). "Impact of a five-dimensional framework on R&D productivity"

### 10.2 Regulatory Guidelines

| Agency | Guideline | Topic |
|--------|-----------|-------|
| FDA | ICH M3(R2) | Nonclinical Safety Studies |
| FDA | ICH S7B | Safety Pharmacology (hERG) |
| FDA | ICH M7 | Genotoxic Impurities |
| EMA | ICH E6(R2) | Good Clinical Practice |
| FDA | 21 CFR 312 | IND Regulations |

### 10.3 Key Metrics

| Parameter | Symbol | Typical Value | Unit |
|-----------|--------|---------------|------|
| IC50 | IC50 | 10 nM - 10 μM | M |
| Binding Affinity | Kd | 1 nM - 1 μM | M |
| Lipophilicity | LogP | 0-3 | dimensionless |
| Solubility | LogS | -4 to 0 | log(M) |
| Permeability | Papp | 50-500 | nm/s |
| Bioavailability | F | 30-100 | % |
| Half-Life | t½ | 4-12 | hours |
| Clearance | CL | 5-20 | mL/min/kg |

### 10.4 WIA Standards

- WIA-INTENT: Natural language interfaces
- WIA-OMNI-API: Universal API gateway
- WIA-CHEM: Chemical structure standards
- WIA-CLINICAL: Clinical trial data
- WIA-GENOMICS: Genomic data integration

---

## Appendix A: Example Calculations

### A.1 IC50 Calculation

```
Given dose-response data:
[Compound] (μM): 0.001, 0.01, 0.1, 1, 10, 100
Inhibition (%): 5, 10, 25, 55, 85, 95

Fit to Hill equation:
Y = Bottom + (Top - Bottom) / (1 + 10^((LogIC50 - X) × HillSlope))

Result:
IC50 = 0.8 μM
Hill Slope = 1.2
R² = 0.99
```

### A.2 Lipinski Compliance

```
Compound: Aspirin
- MW = 180.16 Da ✓ (< 500)
- LogP = 1.19 ✓ (< 5)
- HBD = 1 ✓ (< 5)
- HBA = 4 ✓ (< 10)

Result: Lipinski Compliant (4/4 rules)
```

---

**弘益人間 (홍익인간) · Benefit All Humanity**

*WIA-BIO-009 Specification v1.0*
*© 2025 SmileStory Inc. / WIA*
*MIT License*
